Defilade Capital Management, L.P.
Position in DNLI — Denali Therapeutics Inc.
CIK 2088557
EMERYVILLE, CA
Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,078,793
-$16,032,611 QoQ
Shares Held
391,866
-71.2% QoQ
Ownership
0.245%
of shares outstanding
% of Portfolio
1.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Defilade Capital Management, L.P. holds $290,531,526 across 18 Biotechnology names. DNLI ranks #15 (3.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
682,005 | $39,024,326 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
433,699 | $35,376,827 | |
| 3 | INSM |
INSMED Inc
|
281,838 | $30,049,567 | |
| 4 | ASND |
Ascendis Pharma A/S
|
94,843 | $25,296,524 | |
| 5 | AGIO |
Agios Pharmaceuticals, Inc.
|
546,848 | $20,293,529 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
82,827 | $15,511,840 | |
| 7 | COGT |
Cogent Biosciences, Inc.
|
393,441 | $15,226,166 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
1,490,286 | $14,634,608 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,078,793 | 391,866 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $26,111,404 | 1,359,969 | Shares | Sole | 2026-06-12 | |
| 2025-12-31 | $10,842,331 | 656,713 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||